A new method called target trial emulation (TTE) used real-world data to successfully replicate the findings of a previous clinical trial of Tecfidera (dimethyl fumarate) involving people with relapsing-remitting multiple sclerosis (RRMS), according to a study report. The approach also generated new evidence showing that Tecfidera outperformed glatiramer acetate (sold as Copaxone among others) in…
AAN 2026: AI-powered MS blood test sees growing use in real-world care
Real-world use of Octave Bioscience’s artificial intelligence (AI)-powered blood test for classifying multiple sclerosis (MS) activity has increased substantially in the few years since its commercial U.S. launch. In clinical practice, the multiple sclerosis disease activity (MSDA) test has mainly been used for routine monitoring, with additional uses including baseline assessment, risk stratification at diagnosis,…
AAN2026 Can Tolebrutinib be revived?
Tweet Tolebrutinib which is a irreversible BTK inhibitor was shown in a trial to inhibit non-relapsing progressive MS, but development has been held up in US because of liver damage signals. Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis It failed to…
Barbie Girl in an MS Barbie World
Multiple Sclerosis explores the new pavillion Turns out, I AM a Barbie girl. If Barbie was a perpetually confused, middle aged woman with a slight attitude, MS, and a ton of fatigue. And sneakers. None of those little, pink, plastic heals for me, thank you very much. Actually, this multiple sclerosis blog has nothing to…
AAN 2026: Ocrevus preserves walking, hand function in early RRMS
First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years, according to data from a Phase 3b clinical trial and its extension study. The findings were presented in a talk by Robert Bermel, MD, of the Cleveland Clinic, at the American Academy…
My husband’s MS diagnosis changed everything — and nothing
I had never known anyone personally who had been admitted to a psychiatric hospital. Walking my husband, Rhead, through those doors was one of the strangest moments of my life — not strange in a dramatic way, but strange in the quiet, disorienting way of realizing your life has become something you could not have…
Empowering Myself
I have realized that every time I go to a doctor’s appointment, I walk in already feeling guilty — mentally preparing to defend myself, almost expecting judgment. Before the doctor starts asking about my exercise routines and eating habits, I … Continue reading → Source: blog.mymsaa.org
AAN 2026 The First BTK inhibitor for PPMS to Make-It?
Tweet So it looks like Fenebrutinib may make it where other BTK inhibiotrs has so far failed. The drug inibits relapsing and primary progressive MS in regard to primary progressive MS it is no worse than ocrelizumab and make be a little better. The main difference between fenebrutinib and the past failures are that it…
The price of healing should not be debt
There are moments when living with Multiple Sclerosis feels like a series of calculations between what we can afford, what can wait, and what simply cannot happen at all. Dan recently faced one of those moments when he needed hernia surgery. It wasn’t optional, and it wasn’t related to his MS. But like so many…
Frexalimab AAN20226
Tweet Frexalimab is an indirect B cell inhibitor. It block the natural signal that a B cell gets from T cells and antigen presenting cells as it blocks the ligand (binding bit) to the CD40 receptor. This receptor needs to be stumulated at the same time as the antigen receptor for B cells to be…